301393 昊帆生物
交易中 07-18 09:53:39
资讯
新帖
简况
昊帆生物(301393)186.3万股限售股将于7月14日解禁,占总股本1.72%
证券之星 · 07-14
昊帆生物(301393)186.3万股限售股将于7月14日解禁,占总股本1.72%
昊帆生物欲扩产,盯上人福医药“弃子”,IPO募投项目却龟速推进
投资有道杂志 · 07-09
昊帆生物欲扩产,盯上人福医药“弃子”,IPO募投项目却龟速推进
昊帆生物:2025年一季度股东人数为10,639
证券之星 · 07-08
昊帆生物:2025年一季度股东人数为10,639
这家公司持续亏损!昊帆生物却要溢价250%收购!
市场资讯 · 07-07
这家公司持续亏损!昊帆生物却要溢价250%收购!
扩产能!昊帆生物溢价收购亏损标的杭州福斯特
北京商报 · 07-06
扩产能!昊帆生物溢价收购亏损标的杭州福斯特
昊帆生物拟1.6亿元收购福斯特药业100%股权
财中社 · 07-06
昊帆生物拟1.6亿元收购福斯特药业100%股权
昊帆生物最新公告:拟1.6亿元收购杭州福斯特100%股权
证券之星 · 07-04
昊帆生物最新公告:拟1.6亿元收购杭州福斯特100%股权
6月30日昊帆生物涨5.50%,圆信永丰兴源灵活配置混合A基金重仓该股
证券之星 · 06-30
6月30日昊帆生物涨5.50%,圆信永丰兴源灵活配置混合A基金重仓该股
昊帆生物新提交1件商标注册申请
证券之星 · 06-21
昊帆生物新提交1件商标注册申请
6月9日昊帆生物涨9.97%,圆信永丰兴源灵活配置混合A基金重仓该股
证券之星 · 06-09
6月9日昊帆生物涨9.97%,圆信永丰兴源灵活配置混合A基金重仓该股
昊帆生物:公司在研发、生产各环节建立了完整自主的核心技术体系,并不断创新
证券之星 · 05-27
昊帆生物:公司在研发、生产各环节建立了完整自主的核心技术体系,并不断创新
【CRO概念板块短线拉升 河化股份涨停】CRO概念板块短线拉升,河化股份涨停,金凯生科、睿智医药、诺思格、昊帆生物、义翘神州等纷纷走高。
金融界 · 05-21
【CRO概念板块短线拉升 河化股份涨停】CRO概念板块短线拉升,河化股份涨停,金凯生科、睿智医药、诺思格、昊帆生物、义翘神州等纷纷走高。
5月20日昊帆生物涨7.74%,圆信永丰兴源灵活配置混合A基金重仓该股
证券之星 · 05-20
5月20日昊帆生物涨7.74%,圆信永丰兴源灵活配置混合A基金重仓该股
昊帆生物涨7.74%,开源证券二周前给出“买入”评级
证券之星 · 05-20
昊帆生物涨7.74%,开源证券二周前给出“买入”评级
昊帆生物:公司是全球范围内为数不多的具备全系列多肽合成试剂研发与产业化能力的公司之一
证券之星 · 05-15
昊帆生物:公司是全球范围内为数不多的具备全系列多肽合成试剂研发与产业化能力的公司之一
昊帆生物:截至2025年3月31日的股东人数为10,639
证券之星 · 05-15
昊帆生物:截至2025年3月31日的股东人数为10,639
昊帆生物(301393)2025年一季报简析:营收净利润同比双双增长
证券之星 · 04-28
昊帆生物(301393)2025年一季报简析:营收净利润同比双双增长
昊帆生物(301393)3月31日股东户数1.06万户,较上期增加14.1%
证券之星 · 04-27
昊帆生物(301393)3月31日股东户数1.06万户,较上期增加14.1%
昊帆生物(301393.SZ)发布一季度业绩,归母净利润3479.9万元,增长16.66%
智通财经网 · 04-27
昊帆生物(301393.SZ)发布一季度业绩,归母净利润3479.9万元,增长16.66%
安徽昊帆生物取得 N-(N-(9-芴甲氧羰基)-L-异亮氨羧基)-2-氨基异丁酸的制备方法专利
金融界 · 04-26
安徽昊帆生物取得 N-(N-(9-芴甲氧羰基)-L-异亮氨羧基)-2-氨基异丁酸的制备方法专利
加载更多
公司概况
公司名称:
苏州昊帆生物股份有限公司
所属行业:
化学原料和化学制品制造业
上市日期:
2023-07-12
主营业务:
苏州昊帆生物股份有限公司的主营业务是多肽合成试剂的研发、生产与销售。公司的主要产品是缩合试剂、保护试剂、手性消旋抑制试剂、通用型分子砌块、蛋白质交联剂、蛋白质还原剂、脂质体与脂质纳米粒药用试剂。公司依托在多肽合成试剂行业的优势地位,开发了具有较强技术壁垒与良好市场前景的通用型分子砌块和蛋白质试剂产品,形成了以多肽合成试剂为主,通用型分子砌块和蛋白质试剂为辅的产品体系。
发行价格:
67.68
{"stockData":{"symbol":"301393","market":"SZ","secType":"STK","nameCN":"昊帆生物","latestPrice":54.46,"timestamp":1752803619000,"preClose":55.57,"halted":0,"volume":961500,"delay":0,"changeRate":-0.02,"floatShares":42104799,"shares":108000000,"eps":1.2873,"marketStatus":"交易中","change":-1.11,"latestTime":"07-18 09:53:39","open":55.33,"high":55.54,"low":54.28,"amount":52577200,"amplitude":0.0227,"askPrice":54.51,"askSize":5,"bidPrice":54.46,"bidSize":24,"shortable":0,"etf":0,"ttmEps":1.2873,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1752809400000},"marketStatusCode":2,"adr":0,"adjPreClose":55.57,"symbolType":"stock","openAndCloseTimeList":[[1752802200000,1752809400000],[1752814800000,1752822000000]],"highLimit":61.13,"lowLimit":50.01,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":108000000,"isCdr":false,"pbRate":2.6,"roa":"--","peRate":42.305601,"roe":"1.52%","epsLYR":1.25,"committee":-0.257143,"marketValue":5882000000,"turnoverRate":0.0228,"status":1,"floatMarketCap":2293000000},"requestUrl":"/m/hq/s/301393","defaultTab":"news","newsList":[{"id":"2551319929","title":"昊帆生物(301393)186.3万股限售股将于7月14日解禁,占总股本1.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551319929","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551319929?lang=zh_cn&edition=full","pubTime":"2025-07-14 08:02","pubTimestamp":1752451358,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息整理,昊帆生物于7月14日将有186.3万股限售股份解禁,为公司首发原股东限售股份,占公司总股本1.73%。最近一年内,该股累计解禁1579.95万股,占总股本的14.63%。本次解禁后,公司还有6589.52万股限售股份,占总股本61.01%。昊帆生物主营业务:多肽合成试剂、通用型分子砌块及蛋白质试剂等产品的研发、生产、销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071400001969.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","301393"],"gpt_icon":0},{"id":"2550633938","title":"昊帆生物欲扩产,盯上人福医药“弃子”,IPO募投项目却龟速推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2550633938","media":"投资有道杂志","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550633938?lang=zh_cn&edition=full","pubTime":"2025-07-09 17:17","pubTimestamp":1752052621,"startTime":"0","endTime":"0","summary":"昊帆生物正在计划收购下游客户以扩充产能。昊帆生物本次收购将分两期进行,第一期受让杭州福斯特85%股权,包括予君生物持有的52%股权和10名自然人持有的33%股权。2025年3月,昊帆生物官网公示安徽昊帆《年产1002吨多肽试剂及医药中间体建设项目竣工环境保护验收监测报告》。值得注意的是,昊帆生物的IPO保荐承销费率按照发行规模递增。而昊帆生物上市5个月后,股价开始长期破发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709172046a440033f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709172046a440033f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0070","BK0239","BK0185","301393","BK0229","BK0096","BK0028","600079","BK0012","BK0188"],"gpt_icon":0},{"id":"2549048561","title":"昊帆生物:2025年一季度股东人数为10,639","url":"https://stock-news.laohu8.com/highlight/detail?id=2549048561","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549048561?lang=zh_cn&edition=full","pubTime":"2025-07-08 08:51","pubTimestamp":1751935873,"startTime":"0","endTime":"0","summary":"证券之星消息,昊帆生物(301393)07月07日在投资者关系平台上答复投资者关心的问题。投资者提问:请问:最新的股东人数是多少昊帆生物回复:尊敬的投资者您好,公司依照信息披露相关规定,在各期定期报告中披露对应时点的股东人数。根据已披露的《2025年一季度报告》,截至2025年3月31日的股东人数为10,639,感谢您的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070800006713.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","301393"],"gpt_icon":0},{"id":"2549534480","title":"这家公司持续亏损!昊帆生物却要溢价250%收购!","url":"https://stock-news.laohu8.com/highlight/detail?id=2549534480","media":"市场资讯","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549534480?lang=zh_cn&edition=full","pubTime":"2025-07-07 20:09","pubTimestamp":1751890140,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会! 近日,苏州昊帆生物股份有限公司发布公告称,拟使用1.6亿元自有或自筹资金,购买杭州福斯特药业有限公司100%股权。 本次收购将分两期进行,第一期完成后公司将获得标的公司85%股权,成为其控股股东;第二期将在第一期股权转让工商变更后24个月内实施,届时公司将获得100%股权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2025-07-07/doc-infesafh4261466.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0229","301393"],"gpt_icon":0},{"id":"2549088327","title":"扩产能!昊帆生物溢价收购亏损标的杭州福斯特","url":"https://stock-news.laohu8.com/highlight/detail?id=2549088327","media":"北京商报","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549088327?lang=zh_cn&edition=full","pubTime":"2025-07-06 18:57","pubTimestamp":1751799420,"startTime":"0","endTime":"0","summary":"为提高公司产能,昊帆生物于近期祭出了收购计划。最新公告显示,昊帆生物拟使用1.6亿元自有或自筹资金购买杭州福斯特药业有限公司100%股权。据悉,杭州福斯特作为成熟的生产基地,厂区占地72亩,建筑面积4万多平方米。此前一直面临产能不足的昊帆生物,将通过此次收购获得标的公司的现有富余产能,改善公司产能不足的局面,提高公司产品的供应能力。不过,杭州福斯特去年及今年一季度业绩均出现亏损。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070618590495385f1e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070618590495385f1e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0012","IE00BZ08YR35.GBP","LU0588546209.SGD","301393","603806","LU0307460666.USD","BK0220","IE00BZ08YS42.EUR","IE0005HP3H50.USD","LU0211977185.USD","BK0229","IE00BZ08YT58.USD","BK0070","BK0054","BK0028"],"gpt_icon":0},{"id":"2549249703","title":"昊帆生物拟1.6亿元收购福斯特药业100%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2549249703","media":"财中社","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549249703?lang=zh_cn&edition=full","pubTime":"2025-07-06 16:02","pubTimestamp":1751788940,"startTime":"0","endTime":"0","summary":"7月4日,昊帆生物发布公告,拟使用1.6亿元人民币自有或自筹资金,购买杭州福斯特药业有限公司100%股权。本次收购将分两期进行,第一期完成后公司将获得标的公司85%股权,成为其控股股东;第二期将在第一期股权转让工商变更后24个月内实施,届时公司将获得100%股权。2025年1-3月营业收入为2618万元,净利润亏损844万元。公司认为本次交易不会对其财务状况和经营成果产生重大影响。2025年一季度,昊帆生物实现收入1.35亿元,归母净利润3480万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250706160308979bb888&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250706160308979bb888&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0005HP3H50.USD","BK0229","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","301393","BK0054","BK0012","BK0028","BK0070","LU0588546209.SGD","603806","LU0211977185.USD","IE00BZ08YR35.GBP","LU0307460666.USD","BK0220"],"gpt_icon":0},{"id":"2548392806","title":"昊帆生物最新公告:拟1.6亿元收购杭州福斯特100%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2548392806","media":"证券之星","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548392806?lang=zh_cn&edition=full","pubTime":"2025-07-04 23:21","pubTimestamp":1751642474,"startTime":"0","endTime":"0","summary":"昊帆生物(301393.SZ)公告称,公司拟使用1.6亿元自有或自筹资金,分两期进行,第一期股权转让完成后公司将获得杭州福斯特85%股权,第二期股权转让完成后公司将获得杭州福斯特100%股权。杭州福斯特是一家专注于研发、生产和销售高级中间体、特色原料药并承接部分CDMO业务的企业。本次收购旨在获得标的公司的现有富余产能,改善公司产能不足的局面,提高公司产品的供应能力。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070400038733.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603806","BK0054","LU0588546209.SGD","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","LU0211977185.USD","LU0307460666.USD","IE00BZ08YR35.GBP","BK0012","BK0229","301393","IE0005HP3H50.USD","BK0070","BK0220","BK0028"],"gpt_icon":0},{"id":"2547078065","title":"6月30日昊帆生物涨5.50%,圆信永丰兴源灵活配置混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2547078065","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547078065?lang=zh_cn&edition=full","pubTime":"2025-06-30 16:29","pubTimestamp":1751272162,"startTime":"0","endTime":"0","summary":"证券之星消息,6月30日昊帆生物涨5.50%,收盘报53.56元,换手率9.69%,成交量3.91万手,成交额2.06亿元。重仓昊帆生物的公募基金请见下表:该股最近90天内共有1家机构给出评级,买入评级1家。根据2025基金Q1季报公募基金重仓股数据,重仓该股的公募基金共5家,其中持有数量最多的公募基金为圆信永丰基金的圆信永丰兴源灵活配置混合A。圆信永丰兴源灵活配置混合A目前规模为2.24亿元,最新净值2.044,较上一交易日上涨0.87%,近一年上涨46.6%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025063000021105.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301393","BK0229"],"gpt_icon":0},{"id":"2545821764","title":"昊帆生物新提交1件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2545821764","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545821764?lang=zh_cn&edition=full","pubTime":"2025-06-22 05:00","pubTimestamp":1750539649,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP数据显示,近日苏州昊帆生物股份有限公司新提交1件商标注册申请。商标申请详情如下:今年以来苏州昊帆生物股份有限公司新申请注册商标1件,截止目前公司共持有注册商标48件,另有2件商标尚在注册申请中。通过天眼查大数据分析,苏州昊帆生物股份有限公司共对外投资了5家企业,参与招投标项目9次;财产线索方面有商标信息31条,专利信息91条;此外企业还拥有行政许可15个。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062200000212.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301393","BK0229"],"gpt_icon":0},{"id":"2542809023","title":"6月9日昊帆生物涨9.97%,圆信永丰兴源灵活配置混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2542809023","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542809023?lang=zh_cn&edition=full","pubTime":"2025-06-09 16:32","pubTimestamp":1749457928,"startTime":"0","endTime":"0","summary":"证券之星消息,6月9日昊帆生物涨9.97%创60日新高,收盘报58.15元,换手率18.05%,成交量7.29万手,成交额4.18亿元。重仓昊帆生物的公募基金请见下表:该股最近90天内共有1家机构给出评级,买入评级1家。根据2025基金Q1季报公募基金重仓股数据,重仓该股的公募基金共5家,其中持有数量最多的公募基金为圆信永丰基金的圆信永丰兴源灵活配置混合A。圆信永丰兴源灵活配置混合A目前规模为2.24亿元,最新净值2.0676,较上一交易日上涨0.08%,近一年上涨41.97%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060900020326.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301393","BK0229"],"gpt_icon":0},{"id":"2538481942","title":"昊帆生物:公司在研发、生产各环节建立了完整自主的核心技术体系,并不断创新","url":"https://stock-news.laohu8.com/highlight/detail?id=2538481942","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2538481942?lang=zh_cn&edition=full","pubTime":"2025-05-27 09:06","pubTimestamp":1748307977,"startTime":"0","endTime":"0","summary":"公司于5月10日、11日参与了由中国生化制药工业协会主办的第四届中国多肽产业大会,展位为A50,公司的核心创新产品与突破性技术解决方案吸引了不少客户和行业专家驻足了解、交流。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052700005705.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301393","BK0229"],"gpt_icon":0},{"id":"2537673118","title":"【CRO概念板块短线拉升 河化股份涨停】CRO概念板块短线拉升,河化股份涨停,金凯生科、睿智医药、诺思格、昊帆生物、义翘神州等纷纷走高。","url":"https://stock-news.laohu8.com/highlight/detail?id=2537673118","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537673118?lang=zh_cn&edition=full","pubTime":"2025-05-21 09:46","pubTimestamp":1747791988,"startTime":"0","endTime":"0","summary":"CRO概念板块短线拉升,河化股份涨停,金凯生科、睿智医药、诺思格、昊帆生物、义翘神州等纷纷走高。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/21094650553907.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0229","BK0239","BK0066","BK0077","BK0216","300149","301333","301393","301047","000953","BK0004","BK0071","301509","BK0010"],"gpt_icon":0},{"id":"2536228699","title":"5月20日昊帆生物涨7.74%,圆信永丰兴源灵活配置混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2536228699","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2536228699?lang=zh_cn&edition=full","pubTime":"2025-05-20 16:35","pubTimestamp":1747730136,"startTime":"0","endTime":"0","summary":"证券之星消息,5月20日昊帆生物涨7.74%创60日新高,收盘报53.05元,换手率14.63%,成交量5.9万手,成交额3.04亿元。重仓昊帆生物的公募基金请见下表:该股最近90天内共有1家机构给出评级,买入评级1家。根据2025基金Q1季报公募基金重仓股数据,重仓该股的公募基金共5家,其中持有数量最多的公募基金为圆信永丰基金的圆信永丰兴源灵活配置混合A。圆信永丰兴源灵活配置混合A目前规模为2.24亿元,最新净值1.9443,较上一交易日上涨0.57%,近一年上涨22.41%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052000025176.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","301393"],"gpt_icon":0},{"id":"2536699279","title":"昊帆生物涨7.74%,开源证券二周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2536699279","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2536699279?lang=zh_cn&edition=full","pubTime":"2025-05-20 16:35","pubTimestamp":1747730126,"startTime":"0","endTime":"0","summary":"今日昊帆生物(301393)涨7.74%,收盘报53.05元。2025年4月30日,开源证券研究员余汝意,汪晋发布了对昊帆生物的研报《公司信息更新报告:下游需求释放带来收入高增长,新产能建设快速推进》,该研报对昊帆生物给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为73.6%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为开源证券的余汝意、汪晋。昊帆生物(301393)个股概况:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052000025171.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301393","161027"],"gpt_icon":0},{"id":"2535960158","title":"昊帆生物:公司是全球范围内为数不多的具备全系列多肽合成试剂研发与产业化能力的公司之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2535960158","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535960158?lang=zh_cn&edition=full","pubTime":"2025-05-15 16:06","pubTimestamp":1747296373,"startTime":"0","endTime":"0","summary":"证券之星消息,昊帆生物(301393)05月15日在投资者关系平台上答复投资者关心的问题。投资者提问:请问与公司产品形成市场竞争的主要企业有哪些?他们都上市了吗昊帆生物回复:尊敬的投资者您好,公司是全球范围内为数不多的具备全系列多肽合成试剂研发与产业化能力的公司之一,公司的磷正离子型和脲正离子型多肽合成试剂在国内市场处于领先地位。关于公司竞争对手及行业相关信息,您可通过查阅行业协会公开信息、券商研究报告以及公司披露的相关公告等方式了解。谢谢关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025051500022335.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301393","BK0229"],"gpt_icon":0},{"id":"2535960178","title":"昊帆生物:截至2025年3月31日的股东人数为10,639","url":"https://stock-news.laohu8.com/highlight/detail?id=2535960178","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535960178?lang=zh_cn&edition=full","pubTime":"2025-05-15 16:03","pubTimestamp":1747296210,"startTime":"0","endTime":"0","summary":"证券之星消息,昊帆生物(301393)05月15日在投资者关系平台上答复投资者关心的问题。投资者提问:请问贵公司截止到3.21号股东人数是多少?昊帆生物回复:尊敬的投资者您好,公司依照信息披露相关规定,在各期定期报告中披露对应时点的股东人数。根据已披露的《2025年一季度报告》,截至2025年3月31日的股东人数为10,639,感谢您的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025051500022017.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","301393"],"gpt_icon":0},{"id":"2531986352","title":"昊帆生物(301393)2025年一季报简析:营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2531986352","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531986352?lang=zh_cn&edition=full","pubTime":"2025-04-29 06:21","pubTimestamp":1745878894,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期昊帆生物发布2025年一季报。根据财报显示,昊帆生物营收净利润同比双双增长。截至本报告期末,公司营业总收入1.35亿元,同比上升48.21%,归母净利润3479.9万元,同比上升16.66%。营业收入和归属于上市公司股东净利润创历史新高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042900006933.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301393"],"gpt_icon":0},{"id":"2530438807","title":"昊帆生物(301393)3月31日股东户数1.06万户,较上期增加14.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530438807","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530438807?lang=zh_cn&edition=full","pubTime":"2025-04-27 17:14","pubTimestamp":1745745264,"startTime":"0","endTime":"0","summary":"证券之星消息,近日昊帆生物披露,截至2025年3月31日公司股东户数为1.06万户,较12月31日增加1315.0户,增幅为14.1%。在生物制品行业个股中,昊帆生物股东户数低于行业平均水平,截至3月31日,生物制品行业平均股东户数为3.38万户。从股价来看,2024年12月31日至2025年3月31日,昊帆生物区间涨幅为20.12%,在此期间股东户数增加1315.0户,增幅为14.1%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042700007440.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301393","BK0229"],"gpt_icon":0},{"id":"2530870594","title":"昊帆生物(301393.SZ)发布一季度业绩,归母净利润3479.9万元,增长16.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530870594","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530870594?lang=zh_cn&edition=full","pubTime":"2025-04-27 16:56","pubTimestamp":1745744210,"startTime":"0","endTime":"0","summary":"智通财经APP讯,昊帆生物(301393.SZ)发布2025年第一季度报告,该公司营业收入为1.35亿元,同比增长48.21%。归属于上市公司股东的净利润为3479.9万元,同比增长16.66%。归属于上市公司股东的扣除非经常性损益的净利润为2801.55万元,同比增长8.71%。基本每股收益为0.33元。更多港股重磅资讯,下载智通财经app更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1285829.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["301393"],"gpt_icon":0},{"id":"2530352149","title":"安徽昊帆生物取得 N-(N-(9-芴甲氧羰基)-L-异亮氨羧基)-2-氨基异丁酸的制备方法专利","url":"https://stock-news.laohu8.com/highlight/detail?id=2530352149","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530352149?lang=zh_cn&edition=full","pubTime":"2025-04-26 15:33","pubTimestamp":1745652790,"startTime":"0","endTime":"0","summary":"金融界 2025 年 4 月 26 日消息,国家知识产权局信息显示,安徽昊帆生物有限公司取得一项名为“N-(N-(9-芴甲氧羰基)-L-异亮氨羧基)-2-氨基异丁酸的制备方法”的专利,授权公告号 CN 119350432 B,申请日期为 2024 年 12 月。天眼查资料显示,安徽昊帆生物有限公司,成立于2018年,位于安庆市,是一家以从事化学原料和化学制品制造业为主的企业。企业注册资本10000万人民币。通过天眼查大数据分析,安徽昊帆生物有限公司参与招投标项目16次,专利信息45条,此外企业还拥有行政许可32个。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/26153349913586.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["301393","BK0229"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1752803623526,"stockEarnings":[{"period":"1week","weight":0.0579},{"period":"1month","weight":0.0368},{"period":"3month","weight":0.1981},{"period":"6month","weight":0.4148},{"period":"1year","weight":0.3956},{"period":"ytd","weight":0.3992}],"compareEarnings":[{"period":"1week","weight":0.002},{"period":"1month","weight":0.0382},{"period":"3month","weight":0.0733},{"period":"6month","weight":0.0848},{"period":"1year","weight":0.187},{"period":"ytd","weight":0.0492}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"苏州昊帆生物股份有限公司","boardCode":"AI0026","boardName":"化学原料和化学制品制造业","stockholders":"10639人(较上一季度增加14.10%)","perCapita":"3957股","listingDate":"2023-07-12","address":"江苏省苏州市虎丘区高新区长亭路1号","registeredCapital":"10800万元","survey":" 苏州昊帆生物股份有限公司的主营业务是多肽合成试剂的研发、生产与销售。公司的主要产品是缩合试剂、保护试剂、手性消旋抑制试剂、通用型分子砌块、蛋白质交联剂、蛋白质还原剂、脂质体与脂质纳米粒药用试剂。公司依托在多肽合成试剂行业的优势地位,开发了具有较强技术壁垒与良好市场前景的通用型分子砌块和蛋白质试剂产品,形成了以多肽合成试剂为主,通用型分子砌块和蛋白质试剂为辅的产品体系。","listedPrice":67.68},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"昊帆生物(301393)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供昊帆生物(301393)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"昊帆生物,301393,昊帆生物股票,昊帆生物股票老虎,昊帆生物股票老虎国际,昊帆生物行情,昊帆生物股票行情,昊帆生物股价,昊帆生物股市,昊帆生物股票价格,昊帆生物股票交易,昊帆生物股票购买,昊帆生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"昊帆生物(301393)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供昊帆生物(301393)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}